博濟醫藥(300404.SZ):前三季度臨牀研究服務及臨牀前研究服務毛利率同比基本持平
格隆匯10月30日丨博濟醫藥(300404.SZ)於2023年10月27日進行投資者關係活動,就“根據公司2023年第三季度報吿,毛利率有所下降的原因是?”,公司回覆稱,相較於上年,2023年前三季度,公司臨牀研究服務及臨牀前研究服務毛利率同比基本持平,但2023年前三季度公司未有自主研發項目轉讓及技術成果轉化服務收入,該類業務毛利率較高,因此公司整體毛利率、淨利潤率同比有所下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.